BioTime

BioTime

Employees:
100
Market Cap:
$323.15 million
Revenue:
$5.96 million
5 Year Trend:
6.3%
Net Income:
$43.65 million
NYSE:
BTX

BioTime, Inc. is a clinical-stage biotechnology company in the field of regenerative medicine headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange Market Exchange, ticker symbol BTX. Wikipedia

Employees:
100
Market Cap:
$323.15 million
Revenue:
$5.96 million
5 Year Trend:
6.3%
Net Income:
$43.65 million
NYSE:
BTX

BioTime, Inc. is a clinical-stage biotechnology company in the field of regenerative medicine headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange Market Exchange, ticker symbol BTX. Wikipedia

May 8, 2:16 PM

Co-CEO Dr. Michael D. West to present at World Advanced Therapies & Regenerative Medicine Congress in London on May 17 and 19. On May 17, Dr. West will present at a plenary roundtable discussion with seven fellow senior executives. On May 19 at 11:40 BST, Dr. West will expand upon his presentation last year with an update on deep learning algorithms, titled "Applying Artificial Intelligence to Stem Cell Biology." Read the full press release here: http://bit.ly/2pWxq7d

Dec 14, 6:54 PM

BioTime Achieves Patient Recruitment Milestone in Renevia Pivotal Trial > Crosses Milestone of 50 Patients Randomized in Pivotal Trial > Remains on Track for Top-Line Data by Middle of 2017 $BTX http://bit.ly/2hF6ohA

Dec 12, 4:40 PM

BioTime Co-CEO Dr. Michael West will present at the Global Bioproduction Summit, December 12-13 at the Hilton San Diego Bayfront. Dr. Wests presentation, Methodologies for Human Cell Manufacturing from Pluripotent Stem Cells in the Application of Regenerative Medicine, will be delivered on Tuesday, December 13, at 9:20 a.m. PST Read more: http://bit.ly/2gEdpgE

May 10, 10:06 PM

BioTime Reports First Quarter Results and Recent Corporate Accomplishments - First Cohort in OpRegen Trial Completed - Management to Host Investor Conference Call on May 17, 2016 at 4:30 p.m. ET http://bit.ly/24J9fVB